Contact this trialFirst, we need to learn more about you.
Soluble Guanylate Cyclase Stimulators
Riociguat (Adempas, BAY63-2521) for Pulmonary Hypertension
Recruiting3 awardsPhase 3
Aurora, Colorado
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service